• Martin Westphal, Michael F M James, Sibylle Kozek-Langenecker, Reto Stocker, Bertrand Guidet, and Hugo Van Aken.
• Department of Anesthesiology and Intensive Care, University Hospital of Muenster, Muenster, Germany. martin.westphal@gmx.net
• Anesthesiology. 2009 Jul 1; 111 (1): 187-202.

AbstractWith the development of a new generation of hydroxyethyl starches (HES), there has been renewed interest in their clinical potential. High doses of first- and second-generation HES were associated with adverse effects on renal function, coagulation, and tissue storage, thereby limiting their clinical applicability. Newer HES products have lower molar substitution and in vivo molecular weight, resulting in more rapid metabolism and clearance. In this review article, the differences between HES generations are highlighted, with particular emphasis on the improved safety profile of the third generation products. These improvements have been achieved with no loss of efficacy, and they contradict the assumption that efficacy of HES solutions is directly linked to plasma concentration. The impact of source material on structure and pharmacokinetics is highlighted, and the role of the carrier solution is critically assessed.

12 keywords...

hide…